Heparin-coating of extracorporea circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass

Abstract

This clinical study was performed to evaluate the inhibiting effects of heparin- coated extracorporeal circuits on thrombin formation during cardiopulmonary bypass (CPB). Thirty patients undergoing coronary artery bypass grafting were randomly divided into two groups with (Duraflo II, n=15) orwithout (control, n=15) the use of heparin-coated circuits. Standard systemic heparinization was performed in all the patients before CPB. The results showed that thrombin formation during the first phase of CPB was inhibited by heparin-coating identified by the significantly lower concentrations of thrombin-antithrombin III (TAT) complex formed in plasma in the Duraflo II group than in the control group (p <0.05). Heparin concentrations were higher in the Duraflo II group than in the control group at the end of CPB (p <0.05). However, after release of the aortic crossclamp in the second phase of CPB, thrombin became strongly activated in both the Duraflo II and the control groups indicated by a sharp increase of TAT complex as well as fibrinopeptide A. Thus, Duraflo II heparin-coating reduces thrombin formation in the early phase of CPB, however, this beneficial effect was counteracted after aortic crossclamp release by material-independent stimuli. Therefore, adequate systemic heparinization is still required despite improved haemocompatibility of the circuits offered by heparin-coating.

Get full access to this article

View all access options for this article.

References

van Oeveren W. , Wildevuur ChRH. Blood compatibility of cardiopulmonary bypass circuits. Perfusion 1987; 2: 237-44.

Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 1987; 13: 89-95.

Davis GC , Sobel M. , Salzman EW Elevated plasma fibrinopeptide A and thromboxane B2 levels during cardiopulmonary bypass. Circulation 1980; 61: 808-14.

Bick RL Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost 1985; 11: 249-80.

Pixley RA , Schapira M. , Colman RW Effect of heparin on the inactivation rate of human activated factor XII by antithrombin III. Blood 1985; 66: 198-203.

Gott VL , Whiffen JD , Datten RC Heparin bonding on colloidal graphite surfaces. Science 1963; 142: 1297-98.

Rea WJ , Whitley D. , Eberle JW Long-term membrane oxygenation without systemic heparinization. Trans Am Soc Artif Intern Organs 1972; 18: 316-20.

Fletcher JR , McKee AE , Herman CM Twenty-four hour membrane oxygenation in dogs without anticoagulation. Surgery 1976; 80: 214-23.

Heyman PW , Cho CS , McRea JC , Olsen DB , Kim SW Heparinized polyurethanes: in vitro and in vivo studies. J Biomed Mater Res 1985; 19: 419-36.

10.

Pasche B. , Kodama K. , Larm O. , Olsson P. , Swedenborg J. Thrombin inactivation on surfaces with covalently bonded heparin. Thromb Res 1986; 44: 739-48.

11.

Toomasian JM , Hsu LC , Hirschl RB , Heiss KF , Hultquist KA , Bartlett RH Evaluation of Duraflo II heparin coating in prolonged extracorporeal membrane oxygenation. ASAIO Trans 1988; 34: 410-14.

12.

von Segesser LK , Turina M. Cardiopulmonary bypass without systemic heparinization. Performance of heparin-coated oxygenators in comparison with classic membrane and bubble oxygenators. J Thorac Cardiovasc Surg 1989; 98: 386-96.

13.

Palatianos GM , Dewanjee MK , Kapadvanjwala M. , Novak S. , Sfakianakis GN , Kaiser GA Cardiopulmonary bypass with a surface-heparinized extracorporeal perfusion system. ASAIO Trans 1990; 36: M476-79.

14.

Tong SD , Rolfs MR , Hsu LC Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits . ASAIO Trans 1990; 36: M654-56.

15.

Gu YJ , Wang YS , Chiang BY , Gao XD , Ye CX , Wildevuur ChRH. Membrane oxygenator prevents lung reperfusion injury in canine cardiopulmonary bypass. Ann Thorac Surg 1991 ; 51: 573-78.

16.

Jansen Njg , van Oeveren W. , van der Broek L. et al. Inhibition of the reperfusion phenomena in cardiopulmonary bypass by dexamethasone. J Thorac Cardiovasc Surg 1991 (in press).